Durham startup raises Series A to tackle undruggable proteins, including cancer baddie Myc, with generative AI
The number of ways atoms can be arranged to create potential drugs is so large — 1063, by one estimate — that it exceeds the number of stars in the universe. It’s a number too vast for scientists to ever search through, at least on their own.
But a small startup spun out of Duke University hopes that a little help from AI could change that.
Ten63 Therapeutics raised $15.9 million in Series A financing led by Hatteras Venture Partners, the startup announced Tuesday. Co-founder and CEO Marcel Frenkel told Endpoints News that his company will explore possible structures for small molecule drugs “at a scale that has never been done before.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters